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In this issue of Cancer Cell, Vazquez and colleagues report reduced glycolysis and increased oxidative
phosphorylation in certain melanomas, revealing metabolic plasticity rather than stable Warburg pathophys-
iology. Furthermore, Haq and colleagues (also in this issue of Cancer Cell) show situations where increased
oxidative phosphorylation is required for melanomas to survive inhibition of B-RAF, suggesting investigation
of therapeutic combinations of B-RAF inhibitors with biguanides.Increased glycolysis has been recognized
to be a characteristic of neoplastic cells
since the classic observations of Otto
Warburg. It is now appreciated that the
‘‘Warburg effect’’ does not usually involve
compensation for defects in mitochon-
drial ATP production as originally pro-
posed. Rather, it is a consequence of
genetic lesions that, among other sequel-
lae, alter control systems that regulate
cellular metabolism. While increased
glycolytic flux may provide some benefit
to cancer cells by increasing ATP produc-
tion, recent studies suggest that it is
advantageous mainly because it gener-
ates chemical ‘‘building blocks’’ required
for the anabolic processes that must
occur prior to cell division.
The conspicuous glycolysis of neo-
plastic cells has long provided a rationale
for investigating inhibitors of glycolysis
such as 2-deoxyglucose, but this direc-
tion of research has not yet led to clinical
advances in cancer treatment. Observa-
tions reported in this issue of Cancer
Cell by Haq et al. (2013) and Vazquez
et al. (2013) provide evidence that there
are circumstances in which neoplastic
cells are critically dependent on oxidative
phosphorylation rather than glycolysis, at
least in the context of melanoma. This
may represent a vulnerability that could
be therapeutically exploited.
Both reports show that the lineage-
specific transcription factor MITF upregu-
lates PGC1a in a subset of melanomas,
and, expectedly, this results in increased
oxidative phosphorylation. Haq et al.
(2013) show that mutational B-RAF acti-
vation, a common derangement in mela-
noma, leads to declines in MITF, PGC1a,and oxidative phosphorylation, yielding
a glycolytic phenotype.
B-RAF inhibitors such as vemurafenib
are used in the clinic but commonly
provide only short-term benefit, followed
by the rapid development of drug resis-
tance. Interestingly, when cells with acti-
vated B-RAF are exposed to a B-RAF
inhibitor, they upregulate PGC1a and
demonstrate, at least for a critical period
of time, increased dependency on oxida-
tive phosphorylation. This phenomenon
suggests that the efficacy of B-RAF
inhibitors may be, at least in part, attribut-
able to drug-induced reprogramming of
cellular metabolism, leading to a reduc-
tion of glycolysis and an increased
requirement for oxidative phosphoryla-
tion. While under this stress, cells are
under selective pressure to revert to
a glycolytic phenotype by activating
another oncogene to substitute for the
pharmacologically inhibited B-RAF (Naz-
arian et al., 2010). However, it is pos-
sible that before this reversion takes
place, there is an opportunity for syn-
thetic lethality by combining the kinase
inhibitor with inhibition of oxidative
phosphorylation.
The studies by (Haq et al. (2013) and
Vazquez et al. (2013) are specific to mela-
noma, so it will be of interest to investigate
the generality of the key findings. Many
cancers with prominent glycolytic pheno-
types are treated with kinase inhibitors,
which reduce the oncogenic signaling
that promotes glycolysis, among other
consequences. Most kinase inhibitors
provide a period of benefit followed
by drug resistance. It is possible that
one of several consequences of exposingCancer Cell 2sensitive cells to a kinase inhibitor is
reduction of high glycolytic flux. Apart
from the melanoma data, an example is
provided by glycolytic leukemic cells
driven by BCR-ABL that demonstrate up-
regulated oxidative phosphorylation upon
exposure to imatinib (Gottschalk et al.,
2004; the kinase inhibitor that targets
BCR-ABL).
Consistently, Vazquez et al. (2013)
show that melanomas can be classified
into two groups: a conventional glycolytic
group and a group characterized by high
PGC1a, high rates of oxidative phosphor-
ylation, resistance to oxidative stress, and
aggressive clinical behavior. The latter
group also appears to demonstrate
sensitivity to the targeted inhibition of
oxidative phosphorylation. Experimen-
tally, this point is convincingly made by
knocking down proteins required for
oxidative phosphorylation. However, this
approach is not one that is applicable to
clinical testing.
Are there practical ways to target
oxidative phosphorylation in the clinic?
An initial impression is that this is impos-
sible, as classic inhibitors of cellular respi-
ration such as cyanide are well-known
poisons without a suitable therapeutic
index. However, there are oxidative phos-
phorylation inhibitors that are in common
clinical use, including the antidiabetic
biguanide metformin and the antimalarial
agent atovaquone. Incidentally, the inhibi-
tion of cytochrome b by atovaquone is
effective against Plasmodium falciparum,
not because it inhibits mitochondrial ATP
production (which is not required by the
parasites), but rather because of a re-
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Previewsto regenerate ubiquinone (Painter et al.,
2007). (In Plasmodium falciparum, ubiqui-
none is required as the electron acceptor
for dihydroorotate dehydrogenase, an
essential enzyme for pyrimidine biosyn-
thesis.) Nevertheless, the safety of atova-
quone relates to the fact that it is a better
inhibitor of Plasmodium than human
cytochrome c, so it may not be a strong
candidate for oncology applications.
Metformin, on the other hand, is widely
used for the treatment of type II diabetes,
has a favorable toxicity profile, and is
already under investigation for possible
oncology applications (Pollak, 2012).
There are several hypotheses to explain
the activity of metformin as an antineo-
plastic agent in experimental models.
One involves systemic effects such as
the reduction of insulin levels (which
may be relevant for a subset of patients
where the drug induces significant
declines in insulin, provided their cancers
are insulin responsive). A second hypoth-
esis involves a direct action on neoplastic
cells, characterized by decreased ATP
levels secondary to reduced oxidative
phosphorylation. This can lead to pre-
dominately cytostatic or cytotoxic effects,
depending on the specific characteristics
of targeted cells. In cells with intact
control systems for dealing with energy
stress, ATP deficit leads to the activation
of AMPK, inhibition of mTOR, reduced
energy consumption and growth inhibi-
tion. In cells with loss of function of these
control systems (such as inactivation of
LKB1), the ongoing high level of ATP
consumption, despite reduced oxidative
phosphorylation, leads to an energetic
crisis.
Could metformin or other bigua-
nides be practical inhibitors of oxidative
phosphorylation in the context of the
studies by Haq et al. (2013) and Vazquez
et al. (2013)? This might not require
complete inhibition of oxidative phos-
phorylation, but rather blocking the
increase in oxidative phosphorylation
following PGC1a upregulation.
If further preclinical work provides suffi-
cient evidence that metformin can delay
the development of resistance to vemura-264 Cancer Cell 23, March 18, 2013 ª2013 Efenib or other kinase inhibitors, the safety
profile of biguanides suggests that clinical
trials would be feasible.
However, there are important gaps in
knowledge to consider. First, with clear
credentials as oxidative phosphorylation
inhibitors, why are the biguanides so
different from cyanide in terms of thera-
peutic index? Part of the reason may
relate to whole organism, cellular, and
subcellular pharmacokinetics. Following
oral administration, biguanides accumu-
late in a nonhomogeneous fashion in
different organs, and cellular uptake of
metformin is greatly influenced by the
level of anion transporter OCT1. Further-
more, mitochondrial uptake of biguanides
is facilitated by the membrane potential,
so as biguanide concentration rises at
complex I, the membrane potential falls,
reducing further import and limiting
toxicity. Thus, in vivo, it is not trivial to
determine the extent to which a biguanide
is inhibiting oxidative phosphorylation in
a particular tissue. Thus, it is unclear if
the dose of metformin used in diabetes
patients would be optimal for partial
inhibition of oxidative phosphorylation in
melanoma patients or if phenformin or
other lipophilic biguanides would be
more effective.
There are relevant clues and cautions
in the literature. In tissue culture, bigua-
nides clearly inhibit oxidative phosphory-
lation in transformed cells, often leading
to compensatory increases in glycolysis
(Pollak, 2012). Also, an early report pro-
vided in vitro evidence for synergy
between vemurafenib and metformin
(Niehr et al., 2011). On the other hand,
metformin has been reported in certain
contexts to upregulate VEGF expression,
which is an adaptive response by the
transformed cell to the inhibition of
oxidative phosphorylation. This re-
sponse obviously has the potential for
undesired consequences, although this
research revealed synergy between met-
formin and VEGF inhibitors (Martin et al.,
2012).
Whereas many clinical trials of bigua-
nides for cancer treatment are ongoing,
most were designed with the rationalelsevier Inc.that the reduction of systemic hyper-
insulinemia, if achievable, would be
beneficial. The ongoing trials address
neither hypotheses related to specific
strategic therapeutic combinations of
biguanides with kinase inhibitors nor the
possibility of activity in specific tumor
subsets defined by tumor characteristics
such as PGC1a status. Future studies
aimed at rigorously examining these
possibilities will need to establish, as a
first step, the extent to which clinically
achievable biguanide exposure inhibits
oxidative phosphorylation in neoplastic
tissue in vivo.
Despite the considerable challenges,
the clues concerning the sensitivity of
a subset of cancers to the inhibition of
oxidative phosphorylation, particularly in
the context of resistance to kinase inhibi-
tors, are tantalizing. Further work will
reveal if there are practical opportunities
for synthetic lethality by pharmacologi-
cally limiting the adaptive ability of
transformed cells to upregulate oxidative
phosphorylation when facing stresses
such as oncogenic kinase inhibition.REFERENCES
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